Microdosing (part 3): The path to FDA approval w/ MindMed and Diamond Therapeutics
Business Trip - A podcast by Greg Kubin & Matias Serebrinsky - Thursdays
This is final episode in our 3-part series on microdosing that explores the science, history, and clinical applications. In this episode, we discuss the path to FDA approval for microdosing. We chat with the chief medical officers from Diamond Therapeutics and MindMed about their microdosing clinical programs. Diamond's program uses synthetic psilocybin and is focused on anxiety disorders. Meanwhile, MindMed is focused using low doses of LSD to treat adult ADHD. Our guests are Dr...
